Focus on prescription uptake and payer coverage in the coming quarters, treatment effect durability at 96 weeks supports real-world use. Watch for any confirmatory trial updates that could convert accelerated approval to full approval, further derisking revenue.
RARE drugs
RARE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 2 $26.53entry
- T+1 · 3mo ago −44.03%α −45.07% · $14.85
- T+5 · 2mo ago −45.72%α −44.76% · $14.40
- T+20 · 7w ago −43.35%α −43.02% · $15.03
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ultragenyx announced publication of 96-week Phase 3 data for GENGLYCOS (DTX401) gene therapy in glycogen storage disease Ia, showing sustained cornstarch reduction (61% at Week 96) and maintained glycemic control. The therapy was recently FDA-approved under accelerated approval, this long-term durability data supports the approval and enhances commercial prospects in a well-defined ultra-rare patient population.
Key Facts
- GENGLYCOS (DTX401) was recently FDA approved for GSDIa patients aged 8+ under accelerated approval.
- Phase 3 96-week data showed 61% mean reduction in daily cornstarch intake in both original and crossover groups.
- 33% (original) and 42% (crossover) of participants completely eliminated nighttime cornstarch dosing by Week 96.
- 83% of DTX401-treated participants met or exceeded their own expectations for meaningful cornstarch reduction at Week 48.
- Safety profile acceptable, most common adverse events were transient liver enzyme elevations managed with corticosteroids.
- GSDIa affects approximately 1,500-2,500 patients in the U.S. and 6,000-8,000 worldwide in accessible geographies.
Financial Impact
GENGLYCOS targets an ultra-rare population (~1,500-2,500 U.S.) with high unmet need; revenue potential depends on pricing, but FDA approval with durability data de-risks launch. Prior median analyst revenue estimates for RARE could see upward revision.
Risk Factors
- Accelerated approval contingent on verification of clinical benefit in confirmatory trials.
- Competition from other gene therapies in GSDIa (none currently approved).
- Potential safety issues like immune-mediated hepatotoxicity requiring corticosteroid management.
- Limited patient population caps peak revenue potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3354584 |
Track record
22 reports on RARE
8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers